Login
$LONA
$3.23 -$0.24 (6.92%) Live

$LONA SEC Filings

Filed On Filing
13 Nov 2026 SCHEDULE 13G
04 Nov 2026 SCHEDULE 13G
28 Oct 2026 Form 4: Portman David J., 10% owner

Bought 3,149,470 shares ($9.92B) · Disposed of 5,502,402 Warrant (Open Market Purchase) ($17.3B)

28 Oct 2026 SCHEDULE 13D/A
26 Oct 2026 Form 4: Perceptive Advisors Llc, Director and 2 others

Received 776,648 shares by exercise or conversion ($777)

26 Oct 2026 SCHEDULE 13D/A
22 Sep 2026 8-K: Other Events

In December 2025, as part of a private placement, LeonaBio, Inc. (the “Company”) issued warrants to purchase an aggregate of 23,031,494 shares of its common stock (the “Series A Common Warrants”). The Series A Common Warrants have an exe...

03 Sep 2026 Form 3: Portman David J., 10% owner
31 Aug 2026 SCHEDULE 13D
26 Aug 2026 8-K: Other Events

On August 26, 2026, LeonaBio, Inc. (the “Company”) announced that it had enrolled the 500th subject in its ongoing Phase 3 ELAINE-3 clinical trial (NCT05696626) for lasofoxifene in combination with abemaciclib, a CDK4/6 inhibitor, as a t...

25 Aug 2026 SCHEDULE 13D/A
20 Aug 2026 SCHEDULE 13G/A
14 Aug 2026 10-Q
14 Aug 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

On Track to Complete Enrollment of Phase 3 ELAINE-3 Clinical Trial of Lasofoxifene in ER-positive (ER+), HER2-negative, ESR1-mutated Metastatic Breast Cancer in 4Q 2026 with Topline Data Expected in 2H 2027

10 Jul 2026 Form 4: Perceptive Advisors Llc, Director and 2 others

Granted 28,000 Stock Option (Right to Buy)

09 Jul 2026 Form 4: Perceptive Advisors Llc, Director and 2 others

Granted 28,000 Stock Option (Right to Buy)

24 Jun 2026 Form 4: Callori Fred, Director

Granted 2,333 Stock Option (Right to Buy)

24 Jun 2026 Form 4: Holles Natalie C., Director

Granted 2,333 Stock Option (Right to Buy)

24 Jun 2026 Form 4: Silverman Peter B., Director

Granted 2,333 Stock Option (Right to Buy)

24 Jun 2026 Form 4: Panzara Michael A., Director

Granted 28,000 Stock Option (Right to Buy)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support